Gilead Sciences first launched lenacapavir under the brand name Sunlenca in the United States and European markets in 2022.

Dr Reddy's Laboratories on Wednesday said it has tied up with Gilead Sciences for the manufacture and commercialisation of ...

Shares of Dr. Reddy's Laboratories Ltd. 500124 inched up 0.74% to 6,743.20 Indian rupees Thursday, on what proved to be an ...

Lenacapavir is a US Food and Drug Administration (FDA) approved medication indicated for the treatment of HIV type 1 (HIV-1) ...

Dr. Reddy’s and Hetero partner with Gilead Sciences to manufacture and distribute Lenacapavir for HIV treatment in LMICs.

Dr Reddy’s Laboratories said it has entered into a royalty-free non-exclusive voluntary licensing agreement with Gilead ...

Healthcare: Dr Reddy's Laboratories SA has completed the acquisition through the purchase of shares of Northstar Switzerland ...

Stay updated with the Dr. Reddy's Laboratories Stock Liveblog, your one-stop destination for real-time information and ...

Dr Reddy's Laboratories has completed the acquisition of Haleon plc's global Nicotine Replacement Therapy (NRT) portfolio, ...

Welcome to the Dr. Reddy's Laboratories Stock Liveblog, your ultimate source for real-time updates and analysis of one of the ...

Hyderabad-based pharma giant Dr Reddy’s Ltd finalizes its largest acquisition by buying British Haleon Plc’s non-US nicotine ...

Drug maker Dr Reddy's Laboratories Ltd on Friday (September 27) said it has invested $620 million in its wholly-owned ...